| Literature DB >> 22016837 |
Abstract
The mass-action law based system analysis via mathematical induction and deduction lead to the generalized theory and algorithm that allows computerized simulation of dose-effect dynamics with small size experiments using a small number of data points in vitro, in animals, and in humans. The median-effect equation of the mass-action law deduced from over 300 mechanism specific-equations has been shown to be the unified theory that serves as the common-link for complicated biomedical systems. After using the median-effect principle as the common denominator, its applications are mechanism-independent, drug unit-independent, and dynamic order-independent; and can be used generally for single drug analysis or for multiple drug combinations in constant-ratio or non-constant ratios. Since the "median" is the common link and universal reference point in biological systems, these general enabling lead to computerized quantitative bio-informatics for econo-green bio-research in broad disciplines. Specific applications of the theory, especially relevant to drug discovery, drug combination, and clinical trials, have been cited or illustrated in terms of algorithms, experimental design and computerized simulation for data analysis. Lessons learned from cancer research during the past fifty years provide a valuable opportunity to reflect, and to improve the conventional divergent approach and to introduce a new convergent avenue, based on the mass-action law principle, for the efficient cancer drug discovery and the low-cost drug development.Entities:
Keywords: Drug discovery; ardeemin and immunosuppression; combination index; computer simulation; conservation of animals; diagnostic plot; dose-reduction index; drug combination; drug development; econo-green revolution for bio-research; experimental design; iso-oxazole-fludelone and epothilones; median-effect equation and plot of the mass-action law; pharmacodynamics; polygonogram; small size experiment; synergy definition; therapeutic cure of xenograft tumor; unified theory for dose-effect pharmacodynamics
Year: 2011 PMID: 22016837 PMCID: PMC3196289
Source DB: PubMed Journal: Am J Cancer Res ISSN: 2156-6976 Impact factor: 6.166